Cover Image
Market Research Report
Product code 
1091862

North America Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030

Published: | Inkwood Research | 170 Pages | Delivery time: 2-3 business days

Price

Back to Top
North America Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030
Published: June 21, 2022
Inkwood Research
Content info: 170 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

KEY FINDINGS

The North America Alzheimer's disease therapeutics & diagnostics market is predicted to increase with a 6.46% CAGR between the estimated years 2022 and 2030. Due to anticipated sales growth and the prospect of new therapies gaining market approval, the market is surging in the region.

MARKET INSIGHTS

The North America Alzheimer's disease therapeutics & diagnostics market growth evaluation entails the analysis of Canada and United States. According to the Alzheimer Society of Canada, thousands of new cases of dementia are diagnosed every year. By 2031, the number is expected to increase by 66%.

Since currently available drugs are unable to cure the disease, the benefits of these drugs gradually decrease with time. Further private and public insurers limit drug coverage for individuals who meet the insurance conditions. Therefore, the provincial government steps in and is responsible for Canada's healthcare facilities, which boosts the healthcare industry.

Moreover, advocacy groups like the Alzheimer's Society of Canada are also trying to improve drug coverage. Thus, owing to all the factors above, the Canadian market for Alzheimer's disease diagnostics and therapeutics is expected to register healthy growth over the forecast period.

COMPETITIVE INSIGHTS

Some of the leading companies in the market include: Eli Lilly & Company, Baxter International Inc, Johnson & Johnson, GE Healthcare, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 16809

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING GERIATRIC POPULATION
    • 3.2.2. RISING PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.2.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.2.4. INCREASING PIPELINE DRUGS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.3.3. LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4. KEY ANALYTICS

  • 4.1. TIMELINE OF ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.2. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.3. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.4. KEY MARKET TRENDS
  • 4.5. PORTER'S FIVE FORCES ANALYSIS
    • 4.5.1. BUYERS POWER
    • 4.5.2. SUPPLIERS POWER
    • 4.5.3. SUBSTITUTION
    • 4.5.4. NEW ENTRANTS
    • 4.5.5. INDUSTRY RIVALRY
  • 4.6. KEY BUYING CRITERIA
  • 4.7. SUPPLY CHAIN ANALYSIS
  • 4.8. OPPORTUNITY MATRIX
  • 4.9. VENDOR LANDSCAPE

5. MARKET BY THERAPEUTICS & DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. DISEASE STAGE
      • 5.1.2.1. LATE-STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. GENERIC & BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. BLOOD TEST
    • 5.2.7. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. MARKET SIZE & ESTIMATES
    • 6.1.2. KEY GROWTH ENABLERS
    • 6.1.3. KEY CHALLENGES
    • 6.1.4. KEY PLAYERS
    • 6.1.5. COUNTRY ANALYSIS
      • 6.1.5.1. UNITED STATES
      • 6.1.5.2. CANADA

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIC DEVELOPMENTS
    • 7.1.1. MERGERS & ACQUISITIONS
    • 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 7.1.3. PARTNERSHIPS & AGREEMENTS
    • 7.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
  • 7.2. COMPANY PROFILES
    • 7.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 7.2.2. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 7.2.3. BAXTER INTERNATIONAL INC
    • 7.2.4. BIOGEN INC
    • 7.2.5. COGNOPTIX INC
    • 7.2.6. EISAI CO LTD
    • 7.2.7. ELI LILLY & COMPANY
    • 7.2.8. F HOFFMANN-LA ROCHE
    • 7.2.9. GE HEALTHCARE
    • 7.2.10. JOHNSON & JOHNSON
    • 7.2.11. LUPIN LIMITED
    • 7.2.12. MERCK & CO INC
    • 7.2.13. NOVARTIS AG
    • 7.2.14. PFIZER INC
    • 7.2.15. SIEMENS HEALTHINEERS AG
    • 7.2.16. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.2.17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.2.18. ZYDUS CADILA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
  • TABLE 2: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 3: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 4: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 5: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 6: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 7: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 8: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 9: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 11: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 12: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 13: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 14: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 15: LIST OF MERGERS & ACQUISITIONS
  • TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: KEY MARKET TRENDS
  • FIGURE 3: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 4: KEY BUYING CRITERIA
  • FIGURE 5: SUPPLY CHAIN ANALYSIS
  • FIGURE 6: OPPORTUNITY MATRIX
  • FIGURE 7: VENDOR LANDSCAPE
  • FIGURE 8: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
  • FIGURE 9: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
  • FIGURE 11: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
  • FIGURE 14: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 15: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
  • FIGURE 18: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
  • FIGURE 22: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 23: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 24: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 25: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
  • FIGURE 26: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 28: NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 29: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 30: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: CANADA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)